Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $6.24M |
| Net Income (Most Recent Fiscal Year) | $-84.97M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 623.00 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4106.11% |
| Net Margin (Trailing 12 Months) | -4106.04% |
| Return on Equity (Trailing 12 Months) | -33.02% |
| Return on Assets (Trailing 12 Months) | -31.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.97 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.55 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.48 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.88M |
| Free Float | 39.38M |
| Market Capitalization | $1.92B |
| Average Volume (Last 20 Days) | 0.76M |
| Beta (Past 60 Months) | 1.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.15% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.53% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |